Devendra Hiwase

Devendra Hiwase

Adelaide Medical School

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.


Qualifications: MBBS, MD, FRACP, FRCPA, PhD
Practice Responsibilities: Clinical and laboratory haematology
Specialities: Malignant haematology and stem cell transplantation
Site: Royal Adelaide Hospital (RAH), Haematology Department

Dr Devendra Hiwase is a Consultant Haematologist at the Royal Adelaide Hospital, Senior Lecturer, University of Adelaide and Senior Research Fellow at South Australia Health Medical Research Institute (SAHMRI). He has a special interest in myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML) and stem cell transplantation. In 2012, he started the MDS Research Group and South Australian MDS (SA-MDS) registry. Currently, the Group is involved in clinical and translational research projects, including mutational profiling, identifying novel biomarkers, and exploring the impact of nursing case management and comprehensive geriatric assessment on patients with MDS and related disorders.

Dr Hiwase’s research focuses on the pathogenesis of myeloid neoplasms and has presented his research findings in multiple international and national meetings and published in peer reviewed journals.

He serves on the editorial board of Leukemia Research and as a reviewer for speciality journals such as Haematologica, Leukemia and Lymphoma, as well as British Journal of Haematology. He is also a subject expert reviewer (external) for NHMRC project grants and has made regular contributions to teaching, provision of specialist medical services, and involvement in local and national committees. Dr Hiwase is a fellow of RACP, RCPA and member of the Australasian Leukaemia and Lymphoma Group (ALLG), Haematology Society of Australasia and New Zealand (HSANZ), American Society of Hematology, and a steering committee member of the national MDS and Aplastic Anaemia registry.

Myeloid neoplasms including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) are a group of blood cancers that frequently affect older people. Some patients develop MDS/AML after treatment for their primary cancer (i.e. prostate cancer, breast cancer). This group of patients are known as having therapy-related myeloid neoplasms (T-MN). There are very limited treatment options for T-MN and the survival of these patients is poor. The MDS/AML Research Group focuses on improving the clinical outcome of patients by optimising current therapies and developing new therapies.

Our research group is split into two main arms of MDS/AML research – clinical research and basic science research. The clinical team focuses on patients’ health-related issues including developing global assessment tools to assess patients’ psycho-social needs, quality of life, overall health issues, and treatment-related toxicity. We also aim to improve treatment strategies by studying other factors, such as the management of infections, transfusion support, geriatric support, anticoagulation bleeding support and autoimmune diseases. The basic science team focuses on understanding the molecular pathogenesis of MDS/AML and identify biomarkers (i.e. predisposing mutations, abnormal bone marrow environment caused by long-term chemotherapy and drug resistance proteins) which can potentially change management and developing novel therapeutic approaches. 

  1. South Australian MDS-Database. Grant Funding, Novartis Pharmaceuticals Australia Pty Limited (2018). $60,000. Devendra Hiwase
  2. To evaluate the frequency of clonal haematopoiesis and risk of therapy-related myeloid neoplasm in primary cancer patients treated with chemo/radiotherapy. RAH Research Committee Clinical Project Grant (2018). $50,000. Nimit Singhal, Deepak Singhal, Devendra Hiwase, Chris Hahn, Hamish Scott
  3. Molecular pathogenesis of bone marrow failure and drug resistance in MDS. Miller Bequest HSCGB (2018). $75,886.50. Devendra Hiwase.
  4. Determine the clinical impact of mutation profile in ICUS, MDS and t-MN. Sail for Cancer HSCGB (2018). $38,220.67. Devendra Hiwase.
  5. Molecular profiling to improve diagnosis and develop therapeutic strategy for MDS/MPN overlap syndrome. Miller Bequest HSCGB (2017). $73,718. Ian Lewis, Devendra Hiwase, Amilia Wee
  6. Molecular Profiling of Idiopathic Cytopenia Undetermined Significance to Improve Diagnosis and Develop Prognostic Model. Sail for Cancer HSCGB (2017). $54,345. Ian Lewis, Devendra Hiwase, Amilia Wee
  7. Monitoring efficacy and safety of rHuEpo-lambda in MDS patients. SA-BMC (2017). $30,000. Devendra Hiwase
  8. Role of Inherited and Acquired Genetic Changes in Molecular Pathogenesis of Therapy Related Myeloid Neoplasms. Contributing Haematologist Committee (2017). $25,000.00. Deepak Singhal, Chris Hahn, Prof Richard D’Andrea and A/Prof Ian Lewis
  9. Evaluate role of cellular influx and efflux pumps in Azacitidine resistance. Contributing Haematologist Committee (2017). $25,000.00. Dr. Devendra Hiwase, Ms. Sophie Watts, Ms. Verity Saunders, Prof. Timothy Hughes, Prof. Deborah White, Ms. Amilia Wee
  10. Evaluating role of bone marrow microenvironment and cytokines in MDS pathogenesis. Sail for Cancer (HSCGB) grant $84,389 (2016). Devendra Hiwase, Ian Lewis
  11. Germline variants collaborate with somatic mutation to initiate and/or drive disease primary myelodysplastic syndrome (MDS) and therapy-related myeloid neoplasms (T-MN). NHMRC Near-Miss Grant $50,000.00 (2016). Devendra Hiwase, Chris Hahn, Hamish Scott, Anna Brown, Andreas Schreiber, Michael Osborn, Ian Lewis and Luen Bik To
  12. Comprehensive mutational screening to differentiate between hypoplastic MDS and aplastic anaemia. RAH Research Committee $50,000.00 (2015). Devendra Hiwase, Chris Hahn, Hamish Scott, Andreas Schreiber, Ian Lewis  and Luen Bik To
  13. Correlative Science Proposal Associated with the PINNACLE clinical trial. Novartis Pharmaceuticals Australia. $675,000.00 (2014-2020). Deborah White, Susan Branford, Agnes Yong, David Yeung
  14. Correlative Science Proposal Associated with the ENESTswift clinical trial. Novartis Pharmaceuticals Australia. $500,000.00 (2014-2016). Deborah White, Devendra Hiwase, Agnes Yong
  15. Integration of whole genome single nucleotide polymorphism (SNP) arrays, metaphase cytogenetics and mutation screening by next generation sequencing (NGS) for refining prognosis in lower risk MDS. RAH Research Committee $34,613.00 (2014). Devendra Hiwase, Sarah Moore, Chris Hahn, Hamish Scott, Andreas Schreiber and Luen Bik To
  16. A pilot study exploring the role of geriatric assessment and nursing case manager for patients with MDS. Grant funding from Celgene Australia, $200,000 (2013-2015). Dr. Devendra Hiwase, Prof Luen Bik To and A/Prof Peter Bardy
  17. Differentiating hypoplastic MDS from aplastic anaemia by integration of mutation screening by next generation sequencing (NGS), whole genome single nucleotide polymorphism (SNP) arrays and metaphase cytogenetics. Contributing Haematologist Committee. $30,000.00 (2012). Dr. Devendra Hiwase, Dr. Sarah Moore, Chris Hahn, Prof Hamish Scott, Dr Andreas Schreiber and Prof Luen Bik To
  18. Assessing the role of intracellular azacitidine concentration in MDS-CD34+ progenitors in predicting long term outcome to azacitidine therapy in MDS patients. Grant funding from Celgene US and Australia $154,000.00 (2012-2013). Dr Devendra Hiwase, Prof Luen Bik To and A/Prof Peter Bardy
  19. Detection of karyotype evolution and disease progression by single nucleotide polymorphism arrays (SNP-A) on sequential peripheral blood CD34+ cells in myelodysplastic syndrome (MDS). Contributing Haematologist Committee, $30,000 (2012). Dr Devendra Hiwase, Prof Luen Bik To, A/Prof Peter Bardy and Prof. Junia Melo
  20. Development and testing of a rapid assay for screening of Myelodysplastic syndrome genes for determination of mutant gene signatures. Contributing Haematologist Committee, $62,000 (2011/2012). Dr Devendra Hiwase, Dr. Chris Hahn, Prof Hamish Scott, Prof. Junia Melo and Prof Luen Bik To
  21. South Australian MDS-Database. Grant Funding, Novartis Pharmaceuticals Australia Pty Limited, $210,000 (2010-2014). Dr. Devendra Hiwase and Prof. Luen Bik To
  22. Eradication of leukaemic stem cells using combinations of targeted therapy in chronic myeloid leukaemia. Novartis Pharmaceuticals Australia Pty Limited, $92,293.16 (2012). Dr. Devendra Hiwase
  23. Eradication of leukaemic stem cells using combinations of targeted therapy in Chronic Myelogenous Leukaemia, CML. CSL limited: $36,604.90 (1st July 2010 to Oct 2013). Devendra Hiwase, Angel Lopez and Timothy Hughes

I lead the MDS/AML research group in the South Australian Health and Medical Institute (SAHMRI) and supervise a research assistant, data manager, senior nurse, two PhD students, advanced trainee registrars and medical students. I am actively involved teaching medical students and was awarded “Best teacher of the year” by the University of Adelaide.

    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2019 Co-Supervisor Frailty in Patients with Haematological Malignancies Doctor of Philosophy Doctorate Full Time Dr Angela Teresa Molga
    2018 Co-Supervisor Evaluating Role of Bone Marrow Microenvironment and Cytokine signaling in Pathogenesis of Myelodysplastic Syndrome and Therapy-Related Myeloid Neoplasm Doctor of Philosophy Doctorate Full Time Mrs Monika Maria Kutyna

Connect With Me
External Profiles